Literature DB >> 24649821

microRNAs: a new class of breast cancer biomarkers.

Laoighse Mulrane1, Rut Klinger, Sharon F McGee, William M Gallagher, Darran P O'Connor.   

Abstract

MicroRNAs (miRNAs) are regulatory molecules known to be aberrantly expressed in cancer and contribute to numerous aspects of tumor biology including the initiation, growth and spread of the tumor. With such diverse roles, it is becoming apparent that some may also provide valuable information which may be of use in a clinical setting, demonstrating the potential to act as both screening tools for the stratification of high-risk patients, while informing the treatment decision-making process. There is mounting evidence to suggest that some miRNAs may even provide assistance in the diagnosis of patients with breast cancer. In addition, miRNAs may themselves be considered therapeutic targets, with inhibition or reintroduction of a particular miRNA capable of inducing a response in vivo. This review focuses on miRNAs that have prognostic, diagnostic or predictive potential in breast cancer as well as the possible challenges in the translation of such observations to the clinic.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24649821     DOI: 10.1586/14737159.2014.901153

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  19 in total

Review 1.  Cell-free microRNAs as cancer biomarkers: the odyssey of miRNAs through body fluids.

Authors:  Mohammad Amin Javidi; Amir Hossein Ahmadi; Babak Bakhshinejad; Nazila Nouraee; Sadegh Babashah; Majid Sadeghizadeh
Journal:  Med Oncol       Date:  2014-11-02       Impact factor: 3.064

2.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

3.  Role of microRNA-150 in solid tumors.

Authors:  Fang Wang; Xiubao Ren; Xinwei Zhang
Journal:  Oncol Lett       Date:  2015-04-30       Impact factor: 2.967

4.  microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma.

Authors:  Guofang Guan; Dejun Zhang; Ying Zheng; Lianji Wen; Duojiao Yu; Yanqing Lu; Yan Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Tumor suppressive microRNA-193b promotes breast cancer progression via targeting DNAJC13 and RAB22A.

Authors:  Zhaoying Yang; Miao He; Keren Wang; Guang Sun; Lu Tang; Zheli Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 6.  MicroRNAome genome: a treasure for cancer diagnosis and therapy.

Authors:  Ioana Berindan-Neagoe; Paloma del C Monroig; Barbara Pasculli; George A Calin
Journal:  CA Cancer J Clin       Date:  2014-08-07       Impact factor: 508.702

Review 7.  Belonging to a network--microRNAs, extracellular vesicles, and the glioblastoma microenvironment.

Authors:  Jakub Godlewski; Anna M Krichevsky; Mark D Johnson; E Antonio Chiocca; Agnieszka Bronisz
Journal:  Neuro Oncol       Date:  2014-10-09       Impact factor: 12.300

8.  miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7.

Authors:  Ying Ma; Xing-guo She; Ying-zi Ming; Qi-quan Wan
Journal:  Tumour Biol       Date:  2014-07-30

9.  A ranking-based meta-analysis reveals let-7 family as a meta-signature for grade classification in breast cancer.

Authors:  Yasemin Oztemur; Tufan Bekmez; Alp Aydos; Isik G Yulug; Betul Bozkurt; Bala Gur Dedeoglu
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

Review 10.  Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors.

Authors:  David M Roy; Logan A Walsh
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.